Efficacy and safety of rituximab combined with ESHAP chemotherapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin lymphoma

Clinical Lymphoma and Myeloma

Volumn 7, Issue 6, 2007, Pages 406-412

  Harting, Rekha ^a   Venugopal, Parameswaran ^a   Gregory, Stephanie A ^a   O'Brien, Teresa ^a   Bogdanova, Elena ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Diffuse large B cell lymphoma; Neutropenia; Response

Indexed keywords

ALPHA INTERFERON; BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; METHYLPREDNISOLONE; MITOXANTRONE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; TOSITUMOMAB; TOSITUMOMAB I 131; VINCRISTINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; B CELL LYMPHOMA; BLOOD TOXICITY; CANCER GROWTH; CANCER RELAPSE; CANCER STAGING; CLINICAL ARTICLE; CONTINUOUS INFUSION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROLYTE DISTURBANCE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INJECTION SITE REACTION; LARGE CELL LYMPHOMA; LEUKOCYTE COUNT; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; SIDE EFFECT; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 34447294539     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2007.n.019     Document Type: Article

References (29)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007; CA Cancer J Clin 2007; 57:43-66.
2. Armitage JO, Weisenburger DD, for the Non-Hodgkin's Lymphoma Classification Project. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. J Clin Oncol 1998; 16:2780-2795.
3. National Comprehensive Cancer Network. Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology - v.1.2005. Available at: http://www.nccn.org. Accessed October 25, 2005.
4. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329:987-994.
5. Velasquez WS, McLaughlin P, Tucker S, et al. ESHAP - an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 1994; 12:1169-1176.
6. Coiffier B, Lepage E, Brière J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346:235-242.
7. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005; 23:4117-4126.
8. Lenz G, Dreyling M, Hoster E, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 1992; 23:1984-1992.
9. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999; 17:1244-1253.
10. Aparicio J, Segura A, Garcerá S, et al. ESHAP is an active regimen for relapsing Hodgkin's disease. Ann Oncol 1999; 10:593-595.
11. Ozturk MA, Barista I, Altundag MK, et al. Modified ESHAP as salvage chemotherapy for recurrent or refractory non-Hodgkin's lymphoma: results of a single-center study of 32 patients. Modified etoposide, methylprednisolone, cytarabine and cisplatin. Chemotherapy 2002; 48:252-258.
12. Wang WS, Chiou TJ, Liu JH, et al. ESHAP as salvage therapy for refractory non-Hodgkin's lymphoma: Taiwan experience. Jpn J Clin Oncol 1999; 29:33-37.
13. McLaughlin P, Grillo-López AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16:2825-2833.
14. Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998; 92:1927-1932.
15. Imrie K. Phase III randomized study of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)-like chemotherapy with v without rituximab in patients with CD20-positive diffuse large B-cell non-Hodgkin's lymphoma [National Cancer Institute Web site]. NCI PDQ® Protocol IDs CAN-NCIC-LY9, MINT-M39045, ROCHECAN-NCIC-LY9, NCT00064116. Available at: http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=309053&version= HealthProfessional&protocolsearchid=1907385. Accessed October 25, 2005.
16. Pfreundschuh M. Phase III randomized study of cyclophosphamide, doxorubicin, vincristine, and prednisone with v without rituximab in elderly patients with aggressive non-Hodgkin's lymphoma (randomized portion of the study completed as of 6/2005) [National Cancer Institute Web site]. NCI PDQ® Protocol IDs DSHNHL-1999-1A, EU-20243, NCT00052936. Available at: http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=269015&version= HealthProfessional&protocolsearchid=1907385. Accessed October 25, 2005.
17. Van Oers MHJ, Marcus R, Wolf M, et al. Phase III randomized study of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without rituximab in patients with relapsed follicular non-Hodgkin's lymphoma [National Cancer Institute Web site]. NCI PDQ® Protocol IDs EORTC-20981, NCT00004179, ALLG-NHLLOW4, BNLI-EORTC-20981, CAN-NCIC-LY7, HOVON-H039, NORDIC-EORTC-20981. Available at: http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid= 67393&version=HealthProfessional&protocolsearchid=1907385. Accessed October 25, 2005.
18. Gisselbrecht C. R-ICE v R-DHAP in patients aged 18-65 with relapse diffuse large B cell lymphoma [National Cancer Institute Web site]. NCI PDQ® Protocol IDs CORAL, NCT00137995. Available at: http://www.cancer.gov/search/ ViewClinicalTrials.aspx?cdrid=446828&version=HealthProfessional& protocolsearchid=1907385. Accessed October 25, 2005.
19. Ketterer N, Reyes F, Tilly H, et al. ACVBP v ACVBP plus rituximab in low risk localized diffuse large B-cell lymphoma [National Cancer Institute Web site]. NCI PDQ® Protocol IDs LNH03-1B, NCT00140660. Available at: http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=446849&version= HealthProfessional&protocolsearchid=1907385. Accessed October 25, 2005.
20. Wilson W, Zelenetz AD. Phase III randomized study of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) v etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin and rituximab (EPOCH-R) in patients with previously untreated de novo diffuse large B-cell non-Hodgkin's lymphoma [National Cancer Institute Web site]. NCI PDQ® Protocol IDs CALGB-50303, ECOG-50303, NCT00118209, NCI-05-C-0252. Available at: http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=433265&version= HealthProfessional&protocolsearchid=1907385. Accessed October 25, 2005.
21. Flinn I, Linker C. Phase III randomized study of autologous stem cell transplantation with or without rituximab in patients with relapsed or progressive B-cell diffuse large cell lymphoma [National Cancer Institute Web site]. NCI PDQ® Protocol IDs ECOG-E2499, CALGB-E2499, NCT00052923, CALGB-50205. Available at: http://www.cancer.gov/search/ViewClinicalTrials.aspx? cdrid=258802&version=HealthProfessional&protocolsearchid=1907385. Accessed October 25, 2005.
22. Moskowitz C. Phase III randomized study of rituximab, ifosfamide, carboplatin, and etoposide v rituximab, dexamethasone, cytarabine, and cisplatin as induction therapy followed by high-dose consolidation chemotherapy and autologous stem cell transplantation with v without rituximab as maintenance therapy in patients with relapsed or refractory CD20-positive diffuse large B-cell non-Hodgkin's lymphoma [National Cancer Institute Web site]. NCI PDQ® Protocol IDs MSKCC-03139, CORAL-50-03B, NCT00081146. Available at: http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=360623&version= HealthProfessional&protocolsearchid=1907385. Accessed October 25, 2005.
23. Vellenga E. Phase III randomized study of sequential chemotherapy with or without rituximab followed by ablative chemotherapy and autologous peripheral blood stem cell transplantation in patients with relapsed, CD20 positive, aggressive B-cell non-Hodgkin's lymphoma [National Cancer Institute Web site]. NCI PDQ® Protocol IDs CKVO-2000-06, EU-20042, HOVON-44, HOVON-44/CKVO-2000- 06, NCT00012051. Available at: http://www.cancer.gov/search/ViewClinicalTrials. aspx?cdrid=68476&version=HealthProfessional&protocolsearchid=1907385. Accessed October 25, 2005.
24. Velasquez WS, Cabanillas F, Salvador P, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 1988; 71:117-122.
25. Pettengell R, Gurney H, Radford JA, et al. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood 1992; 80:1430-1436.
26. Ferrajoli A, O'Brien S, Faderl S, et al. Rituximab plus GM-CSF for patients with chronic lymphocytic leukemia. Blood 2000; 106:214a (Abstract #721).
27. Rossi J-F, Lu ZY, Quittet P, et al. Rituximab activity is potentiated by GM-CSF in patients with relapsed, follicular lymphoma: results of a phase II study. Blood 2005; 106:684a (Abstract #2432).
28. Venugopal P, Sivaraman S, Huang X, et al. Effects of cytokines on CD20 antigen expression in tumor cells from patients with chronic lymphocytic leukemia. Leuk Res 2000; 24:411-415.
29. Hicks L, Buckstein R, Piliotis E, et al. Rituximab + ESHAP as salvage chemotherapy for relapsed/refractory aggressive non-Hodgkins lymphoma: a phase II trial. Blood 2004; 104:392b (Abstract #5230).